Filing Flows › Sutro Biopharma (STRO) › Q1 2026 › vs Q1 2025
Sutro Biopharma (STRO) Q1 2026 vs Q1 2025 (year over year)
Sutro Biopharma's revenue fell $2.9M (-17%) from $17.4M in Q1 2025 to $14.5M in Q1 2026.
Sutro Biopharma, Q1 2026: revenue $14.5M (-16% year over year), operating margin -204.2%, net loss $38.5M, operating cash flow −$42.3M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $14.5M | $17.4M | −$2.9M | -17% |
| Income tax benefit | $15K | −$7K | $22K | — |
| Net loss | $38.5M | $76.0M | −$37.5M | -49% |
| Costs & expenses | $53.0M | $93.4M | −$40.3M | -43% |
| Operating costs | $44.2M | $85.9M | −$41.7M | -49% |
| Interest & other, net | $8.8M | $7.4M | $1.4M | +19% |
| Research & development | $36.6M | $51.6M | −$15.0M | -29% |
| General & admin | $7.6M | $13.3M | −$5.7M | -43% |
| Operating cash sources | $45.1M | $75.3M | −$30.2M | -40% |
| Depreciation & amortization | $1.3M | $1.9M | −$622K | -33% |
| Share-based compensation | $1.6M | $5.5M | −$4.0M | -72% |
| Cash used in operations | $42.3M | $67.9M | −$25.6M | -38% |
| Net loss absorbed | $38.5M | $76.0M | −$37.5M | -49% |
| Working capital & other | $6.6M | −$647K | $7.3M | — |
Questions
How much did Sutro Biopharma's revenue grow year over year in Q1 2026?
Sutro Biopharma's revenue fell $2.9M (-17%) from $17.4M in Q1 2025 to $14.5M in Q1 2026.